JRJohanna Risse

Johanna Risse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johanna Risse has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neue somatische genomische Therapien – neue ethische Herausforderungen?

    by Johanna Risse

    Die Entwicklung von CRISPR/Cas-basierten Therapien wird vielfach als eine Technik betrachtet, die potenziell eine fundamentale Transformation sowohl der wissenschaftlichen Forschung als auch ihrer klinischen Anwendung bewirken kann. Im Gegensatz zu Eingriffen in die Keimbahn findet die somatische (d. h. die nicht vererbbare) CRISPR/Cas-basierte genomische Intervention in der Diskussion über neue ethische Herausforderungen nur wenig Beachtung. Auf der Grundlage einer Analyse der konzeptionellen Unterschiede zwischen klassischer Genaddition und CRISPR/Cas-basierten Verfahren wird für eine postgenomische Ethik argumentiert, die neue ethische Herausforderungen neuer somatischer genomischer Therapien analysiert und adressiert.

  • Nationale Strategie für gen- und zellbasierte Therapien, written by Berlin Institute for Health at Charité (BIH)

    by Johanna Risse

    "Nationale Strategie für gen- und zellbasierte Therapien, written by Berlin Institute for Health at Charité (BIH)" published on 29 Aug 2025 by Brill | mentis.

  • Open Access

    “Snip, snip, cure”? Philosophical, legal and biomedical perspectives on novel somatic genomic therapies

    by Johanna Risse, Lothar Pietrek, Tobias Cantz, Merlin Krzemien, Jan Schnalke, Reto Eggenschwiler, Thomas Heinemann, Hans-Georg Dederer

    The advent of innovative techniques, such as the CRISPR/Cas system, has opened up a new range of possibilities for modifying the genome, with the potential to address previously unmet therapeutic needs of patients with genetic diseases. These new possibilities have not only raised ethical concerns but also challenged existing classifications of genome modification techniques. While the legal status of some of these new therapies remains uncertain, there is an ongoing debate within philosophy of biology about the information-related metaphors adopted by scientists to describe and classify the genome and its therapeutic modification. Given the continuing advance of new genomic therapies, we show, employing an interdisciplinary approach, that a comprehensive framework for the classification of these technologies is needed to resolve legal and philosophical issues. The first section provides an analysis of the current state of novel genome-modifying techniques in medical genetics. In the second section, we assess the regulatory status of these techniques within the European regulatory framework for advanced therapy medicinal products (ATMPs). Drawing on these results, we argue in the third section from a philosophical perspective that metaphors, such as ‘editing’ the genome, which are based on a conception of the genome as linear information, cannot adequately capture the breadth of advanced genomic technologies. To accurately categorise these techniques in a manner that meets their diverse applications, we propose introducing the umbrella term ‘somatic genomic therapies’ (SGTs). Urging an integrative approach to defining and classifying new technologies in medical genetics, we advocate for the development of an integrative concept of SGTs.


  • Open Access

    Towards ethical drug pricing: the European Orphan Genomic Therapies Fund

    by Johanna Risse, Merlin Krzemien, Jan Schnalke, Thomas Heinemann

    An increasing number of novel genomic therapies are expected to become available for patients with rare or ultra-rare diseases. However, the primary obstacle to equal patient access to these orphan genomic therapies are currently very high prices charged by manufacturers in the context of limited healthcare budgets. Taking into account ethical pricing theories, the paper proposes the implementation of a pricing infrastructure covering all European member states, which has the potential to promote distributive justice while maintaining the attractiveness of genomic therapy development.